Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Grübler, MR; Gaksch, M; Kienreich, K; Verheyen, ND; Schmid, J; Müllner, C; Richtig, G; Scharnagl, H; Trummer, C; Schwetz, V; Meinitzer, A; Pieske, B; März, W; Tomaschitz, A; Pilz, S.
Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension.
J Steroid Biochem Mol Biol. 2018; 175(2):157-163
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Gaksch Martin
Grübler Martin Robert
Kienreich Katharina
Maerz Winfried
Meinitzer Andreas
Pieske Burkert Mathias
Pilz Stefan
Richtig Georg
Scharnagl Hubert
Schmid Johannes
Theiler-Schwetz Verena
Tomaschitz Andreas
Trummer Christian
Verheyen Nicolas Dominik
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Accumulating evidence has proposed a correlation between vitamin D (25(OH)D) insufficiency and cardiovascular (CV) disease. Vitamin D associated effects on endothelial function have been suggested to be a possible culprit. The present study investigated the association of vitamin D3 treatment on markers of endothelial dysfunction in patients with arterial hypertension. The Styrian Vitamin D Hypertension Trial is a double-blind, placebo-controlled, single-centre study conducted at the Medical University of Graz, Austria. A total of 200 study participants with arterial hypertension and 25(OH)D levels below 30ng/mL were enrolled. The study participants were randomized to receive 2800 IU of vitamin D3 per day as oily drops (n=100) or placebo (n=100) for a duration of eight weeks. The present study uses an analysis of covariance (ANCOVA) to investigate the effect of vitamin D3 treatment on symmetric (SDMA) and asymmetric dimethylarginine (ADMA). A total of 187 participants (mean [SD] age 60.0 [11.3] years; 47% women; 25(OH)D 21.2 [5.6]ng/mL; mean systolic blood pressure of 131.4 [8.9] mmHg on a median of 2 antihypertensive drugs) completed the trial. Mean treatment effect was -0.004 (95%CI [-0.03 to 0.04]; P=0.819) on ADMA and 0.001 (95%CI [-0.05 to 0.05]; P=0.850) on SDMA. In the subgroup analysis patients with a 25(OH)D concentration <20ng/mL had a significant increase in their log l-arginine/ADMA ratio (mean treatment effect 18.4 95%CI [1.84-34.9]μmol/L/μmol/L; P=0.030). ClinicalTrials.gov Identifier: NCT02136771 EudraCT number: 2009-018125-70 CONCLUSIONS: Vitamin D3 supplementation in hypertensive patients with low 25-hydroxyvitamin D has no significant effect on ADMA and SDMA. Copyright © 2016 Elsevier Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Analysis of Variance -
Arginine - analogs & derivatives
Arginine - blood
Blood Pressure - drug effects
Cholecalciferol - administration & dosage
Dietary Supplements -
Double-Blind Method -
Female -
Humans -
Hypertension - blood
Hypertension - complications
Hypertension - diet therapy
Male -
Middle Aged -
Vitamin D - analogs & derivatives
Vitamin D - blood
Vitamin D Deficiency - blood
Vitamin D Deficiency - complications
Vitamin D Deficiency - diet therapy

Find related publications in this database (Keywords)
Vitamin D deficiency
Arterial hypertension
Endocrinology
Cardiovascular disease
Endothelial dysfunction
Vitamin D
© Meduni Graz Impressum